Cargando…
Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways
BACKGROUND: High levels of thymidine kinase 1 (TK1) and thymidine phosphorylase (TYMP) are key molecular targets by thymidine therapeutics in cancer treatment. The dual roles of TYMP as a tumor growth factor and a key activation enzyme of anticancer metabolites resulted in a mixed outcome in cancer...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374574/ https://www.ncbi.nlm.nih.gov/pubmed/25881156 http://dx.doi.org/10.1186/s12885-015-1149-5 |
_version_ | 1782363510480568320 |
---|---|
author | Wei, Qiong Liu, Haijuan Zhou, Honghao Zhang, Dejun Zhang, Zhiwei Zhou, Qibing |
author_facet | Wei, Qiong Liu, Haijuan Zhou, Honghao Zhang, Dejun Zhang, Zhiwei Zhou, Qibing |
author_sort | Wei, Qiong |
collection | PubMed |
description | BACKGROUND: High levels of thymidine kinase 1 (TK1) and thymidine phosphorylase (TYMP) are key molecular targets by thymidine therapeutics in cancer treatment. The dual roles of TYMP as a tumor growth factor and a key activation enzyme of anticancer metabolites resulted in a mixed outcome in cancer patients. In this study, we investigated the roles of TK1 and TYMP on a thymidine quinoxaline conjugate to evaluate an alternative to circumvent the contradictive role of TYMP. METHODS: TK1 and TYMP levels in multiple liver cell lines were assessed along with the cytotoxicity of the thymidine conjugate. Cellular accumulation of the thymidine conjugate was determined with organelle-specific dyes. The impacts of TK1 and TYMP were evaluated with siRNA/shRNA suppression and pseudoviral overexpression. Immunohistochemical analysis was performed on both normal and tumor tissues. In vivo study was carried out with a subcutaneous liver tumor model. RESULTS: We found that the thymidine conjugate had varied activities in liver cancer cells with different levels of TK1 and TYMP. The conjugate mainly accumulated at endothelial reticulum and was consistent with cytosolic pathways. TK1 was responsible for the cytotoxicity yet high levels of TYMP counteracted such activities. Levels of TYMP and TK1 in the liver tumor tissues were significantly higher than those of normal liver tissues. Induced TK1 overexpression decreased the selectivity of dT-QX due to the concurring cytotoxicity in normal cells. In contrast, shRNA suppression of TYMP significantly enhanced the selective of the conjugate in vitro and reduced the tumor growth in vivo. CONCLUSIONS: TK1 was responsible for anticancer activity of dT-QX while levels of TYMP counteracted such an activity. The counteraction by TYMP could be overcome with RNA silencing to significantly enhance the dT-QX selectivity in cancer cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1149-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4374574 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43745742015-03-27 Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways Wei, Qiong Liu, Haijuan Zhou, Honghao Zhang, Dejun Zhang, Zhiwei Zhou, Qibing BMC Cancer Research Article BACKGROUND: High levels of thymidine kinase 1 (TK1) and thymidine phosphorylase (TYMP) are key molecular targets by thymidine therapeutics in cancer treatment. The dual roles of TYMP as a tumor growth factor and a key activation enzyme of anticancer metabolites resulted in a mixed outcome in cancer patients. In this study, we investigated the roles of TK1 and TYMP on a thymidine quinoxaline conjugate to evaluate an alternative to circumvent the contradictive role of TYMP. METHODS: TK1 and TYMP levels in multiple liver cell lines were assessed along with the cytotoxicity of the thymidine conjugate. Cellular accumulation of the thymidine conjugate was determined with organelle-specific dyes. The impacts of TK1 and TYMP were evaluated with siRNA/shRNA suppression and pseudoviral overexpression. Immunohistochemical analysis was performed on both normal and tumor tissues. In vivo study was carried out with a subcutaneous liver tumor model. RESULTS: We found that the thymidine conjugate had varied activities in liver cancer cells with different levels of TK1 and TYMP. The conjugate mainly accumulated at endothelial reticulum and was consistent with cytosolic pathways. TK1 was responsible for the cytotoxicity yet high levels of TYMP counteracted such activities. Levels of TYMP and TK1 in the liver tumor tissues were significantly higher than those of normal liver tissues. Induced TK1 overexpression decreased the selectivity of dT-QX due to the concurring cytotoxicity in normal cells. In contrast, shRNA suppression of TYMP significantly enhanced the selective of the conjugate in vitro and reduced the tumor growth in vivo. CONCLUSIONS: TK1 was responsible for anticancer activity of dT-QX while levels of TYMP counteracted such an activity. The counteraction by TYMP could be overcome with RNA silencing to significantly enhance the dT-QX selectivity in cancer cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1149-5) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-21 /pmc/articles/PMC4374574/ /pubmed/25881156 http://dx.doi.org/10.1186/s12885-015-1149-5 Text en © Wei et al.; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Wei, Qiong Liu, Haijuan Zhou, Honghao Zhang, Dejun Zhang, Zhiwei Zhou, Qibing Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways |
title | Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways |
title_full | Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways |
title_fullStr | Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways |
title_full_unstemmed | Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways |
title_short | Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways |
title_sort | anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374574/ https://www.ncbi.nlm.nih.gov/pubmed/25881156 http://dx.doi.org/10.1186/s12885-015-1149-5 |
work_keys_str_mv | AT weiqiong anticanceractivityofathymidinequinoxalineconjugateismodulatedbycytosolicthymidinepathways AT liuhaijuan anticanceractivityofathymidinequinoxalineconjugateismodulatedbycytosolicthymidinepathways AT zhouhonghao anticanceractivityofathymidinequinoxalineconjugateismodulatedbycytosolicthymidinepathways AT zhangdejun anticanceractivityofathymidinequinoxalineconjugateismodulatedbycytosolicthymidinepathways AT zhangzhiwei anticanceractivityofathymidinequinoxalineconjugateismodulatedbycytosolicthymidinepathways AT zhouqibing anticanceractivityofathymidinequinoxalineconjugateismodulatedbycytosolicthymidinepathways |